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Abstract
Duchenne Muscular Dystrophy is a chronic, progressive and ultimately fatal
skeletal muscle wasting disease characterised by sarcolemmal fragility and
intracellular Ca2+ dysregulation secondary to the absence of dystrophin. Mounting
literature also suggests that the dysfunction of key energy systems within the
muscle may contribute to pathological muscle wasting by reducing ATP availability
to Ca2+ regulation and fibre regeneration. No study to date has biochemically
quantified and contrasted mitochondrial ATP production capacity by dystrophic
mitochondria isolated from their pathophysiological environment such to determine
whether mitochondria are indeed capable of meeting this heightened cellular ATP
demand, or examined the effects of an increasing extramitochondrial Ca2+
environment. Using isolated mitochondria from the diaphragm and tibialis anterior
of 12 week-old dystrophin-deficient mdx and healthy control mice (C57BL10/ScSn)
we have demonstrated severely depressed Complex I-mediated mitochondrial ATP
production rate in mdx mitochondria that occurs irrespective of the macronutrient-
derivative substrate combination fed into the Kreb’s cycle, and, which is partially,
but significantly, ameliorated by inhibition of Complex I with rotenone and
stimulation of Complex II-mediated ATP-production with succinate. There was no
difference in the MAPR response of mdx mitochondria to increasing
extramitochondrial Ca2+ load in comparison to controls, and 400 nM
extramitochondrial Ca2+ was generally shown to be inhibitory to MAPR in both
groups. Our data suggests that DMD pathology is exacerbated by a Complex I
deficiency, which may contribute in part to the severe reductions in ATP production
previously observed in dystrophic skeletal muscle.
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Duchenne Muscular Dystrophy (DMD) is a fatal neuromuscular disease
characterised by progressive fibre necrosis secondary to the absence of the protein
dystrophin from the sarcolemma [1]. This leads to severe muscle wasting and
weakness, and eventually death in all patients afflicted with the disease, usually by
the third decade of life [2]. A prominent yet commonly ignored feature of DMD is
compromised bioenergetical status. A 50% deficit in resting ATP levels in
dystrophic skeletal muscle has been reported [3, 4] which is likely reflective of
both an increased demand for calcium (Ca2+) buffering, satellite cell cycling and
muscle regeneration, alongside an inability of cellular energy systems to match this
heightened demand with sufficient ATP production. Indeed, functional aberra-
tions in key intracellular energy systems, including the mitochondria, have been
consistently reported in the literature [4–8]. It is likely that these aberrations are
strongly associated with the drastically increased intracellular [Ca2+] that is
observed in dystrophin-deficient myofibres [9], and contribute significantly to the
muscle wasting phenotype of DMD.
Mitochondria are important regulators of [Ca2+]i in skeletal muscle and work
synchronously with the sarcoplasmic reticulum (SR) to maintain a resting [Ca2+]i
of approximately 50 nM, and handle 100-fold functional oscillations of up to
5 mM during excitation-contraction coupling. Increasing [Ca2+]mit during activity
is thought to provide functional benefits to the muscle whereby oxidative ATP
production can be matched to demand at the cross-bridge level [10, 11]. Ca2+ is
thus considered a positive stimulator of oxidative phosphorylation (OXPHOS)
[10–13] and in dystrophic muscle where resting [Ca2+]i is demonstrably two-fold
higher [14–16] the stimulus for mitochondrial ATP production should,
theoretically, be elevated.
A reduced capacity for OXPHOS by dystrophic mitochondria has, however,
been consistently reported in the literature [5–8, 17–20], Assessment of O2
consumption indicates a 30–35% decrease in mitochondrial respiration rates of
both type I and type II fibres [8, 21] and mdx myoblasts [7] yet it is unclear as to
whether reduced OXPHOS capacity is attributable to any specific metabolic
pathway or intrinsic to the mitochondria. Chi et al. [22] has reported impaired
glycolysis and hence carbohydrate metabolism, but speculate that increased fatty
acid metabolism adequately compensates this deficit. Conversely, Kuznetsov et al.
[6] report a 50% reduction in electron transport chain (ETC) enzyme activity but
no change in glycolysis or TCA cycling rates, whilst Even et al. [5] report normal
glycolytic but abnormal TCA activity.
A reason for these fundamentally different results might be that mitochondria
are particularly adaptive to the environment in which they exist, and that the
metabolic studies performed thus far have failed to ascertain the functional and/or
pathophysiological status of the fibres/cells/myotubes that assays have been
performed upon. In particular, mitochondrial function is highly dependent upon
the calcium status of the cell such that highly necrotic fibres/cells are likely to have
a large proportion of mitochondria that are overloaded with calcium and
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morphologically and/or functionally altered. As such, isolated mitochondria
preparations are useful assay platforms for the investigation of disease states as the
complex pathology-induced environment within the cell is effectively removed
allowing intrinsic defects and/or persistent adaptations within the mitochondria
to be determined. Removing mitochondria from the cellular environment allows
dysfunction specific to the mitochondria to be determined, and for artificial
environments around the mitochondria to be created to determine the impact of
isolated variables on OXPHOS.
The present study is the first to directly quantify ATP production by dystrophic
mdx mouse skeletal muscle mitochondria using a biochemical luciferin/luciferase
reporter system. In particular, mitochondria isolated from diaphragm - which
unlike hind limb muscle, parallels the progressive severity evident in human DMD
[23] – was assessed. We aimed to characterise the effect of TCA substrate
manipulation and increasing environmental [Ca2+] on mitochondrial ATP
production rate (MAPR) to determine if mdx mitochondria respond normally to
an artificially induced-dystrophinopathic (i.e. high [Ca2+]i) environment.
Materials and Methods
Ethics Statement
All experiments were approved by the Animal Ethics Experimentation
Committee, Victoria University (AEETH 07/02), and conformed to the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes (7th
edition, National Health and Medical Research Council (NHMRC), 2004).
Animals were housed in pairs and provided enrichment, and all procedures were
conducted to maximise animal welfare by following the Guidelines to Promote the
Wellbeing of Animals used for Scientific Purposes (NHMRC, 2008).
Animals
Age-matched normal C57BL/10ScSn (13.17¡0.21 weeks) and dystrophic mdx
(12¡0.5 weeks) mice were sourced from the Animal Resources Centre (Western
Australia, Australia), housed at the Victoria University Animal Facility (Werribee
Campus, Victoria, Australia) on a 12:12 hour light-dark cycle and were permitted
ad libitum access to food and water. A total of 36 animals were used in this study:
For MAPR, CS function, and mitochondrial protein experiments n510 for both
control and mdx groups; for the mitochondrial swelling experiment n58 for both
control and mdx groups.
The diaphragm was selected to study the full range of metabolic substrates in
this study due to its human-DMD comparative phenotype [23], whereas a smaller
subset of substrates (PPKM and S+R) was used to assess TA. On the day of
experimentation, animals were anaesthetised (sodium pentobarbitone; 60 mg/kg;
IP) and both muscle were excised for mitochondrial isolation.
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Mitochondrial Isolation
For the MAPR assay, mitochondria were isolated according to adapted methods
of Wibom et al. [24] and is described briefly. Muscles were dissected free of
connective tissue, finely minced and ground-glass homogenised in Solution A
(KCl 100 mM; TRIS 50 mM; MgCl2.6H2O 5 mM; ATP 1.8 mM; EDTA 1 mM;
pH 7.2) (M1). M1 homogenate was centrifuged (650 G, 4 C˚, 3 mins) and the
supernatant retained and re-centrifuged (15000 G, 4 C˚, 3 mins). The mitochon-
drial pellet was retained and re-suspended in Solution A with graded fine-bore
glass pasteur pipettes and re-centrifuged (15000 G, 4 C˚, 3 mins). This step was
repeated. The final pellet was re-suspended in 200 mL mitochondrial storage
solution (200 ml, Solution B containing: sucrose 180 mM; KH2PO4 35 mM; Mg
Acetate 5 mM; EDTA 1 mM; pH 7.5 with KOH) to yield the final mitochondrial
suspension (M2). M2 suspension was diluted 1:5 with Solution B and a volume
portion was snap frozen for later determination of mitochondrial protein content,
a volume retained on ice for determination of citrate synthase activity and the
remaining volume further diluted 1:5 with ATP monitoring reagent containing
firefly luciferase (AMR; containing: sucrose 180 mM; KH2PO4, 35 mM; Mg
acetate, 5 mM; EDTA, 1 mM; Na4P2O7 mM; and 1% BSA, pH 7.5 with KOH;
reconstituted FL-AAM ATP assay mix (Sigma Chemical Company, MO, USA)
containing luciferase and luciferin) to yield the working mitochondrial suspension
(MS). MS was used immediately to measure ATP production rate.
Measurement of Mitochondrial ATP Production Rate (MAPR)
Substrate cocktails of pyruvate and malate (1 mM each; P+M); palmitoyl- -
carnitine (0.005 mM) and malate (10 mM) (PC+M); a-ketoglutarate (10 mM; a-
KG); pyruvate (1 mM), palmitoyl--carnitine (0.005 mM), a-ketoglutarate
(10 mM) and malate (10 mM) (PPKM); and succinate (20 mM and rotenone
(0.1 mM) were prepared in AMR solution with a final [ADP] of 0.04 mM to
stimulate the various entry points for substrate channelling into the TCA to fuel
OXPHOS.
To test the effects of increasing extra-mitochondrial [Ca2+] on MAPR, a series
of stock CaCl2 solutions were prepared to give final concentrations in the
substrate cocktails of 50, 100, 200 and 400 nM, respectively. To determine the
effects of [Ca2+] on MAPR for both diaphragm and TA, only PPKM and S+R
substrates were utilised as these substrates give a good indication of how each of
NADH- and FADH2-stimulated OXPHOS is affected by Ca
2+, respectively.
MAPR was determined using firefly luciferase (Sigma, Australia) according to
the methods of Wibom et al. [25] as previously used in our laboratory [26, 27].
Each well was calibrated with an internal ATP standard at the commencement of
the assay. Basal ATP production was measured and ATP synthesis induced via the
addition of ADP. [26, 27]. For all experiments, a background assay was performed
containing mitochondria with no substrate to determine non-mitochondrial ATP
production via the adenylate kinase and other non-specific reactions (see S1
Table). Linear, time-dependent ATP production was confirmed for all assays.
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Data is the average MAPR of triplicate readings and corrected for intact
mitochondrial yield (%) as determined by sequential citrate synthase activity
analysis. Control (n510) and mdx (n510) group sizes were utilised for these
experiments.
Measurement of Citrate Synthase
CS synthase activity was measured spectrophotometrically (412 nm, 25 C˚),
according to the methods of Srere [28]. CS activity was measured in the original
mitochondrial extract on the day of experimentation post-MAPR assay (CSbefore),
in the original mitochondrial extract containing 1% Triton-X after periodical
snap-freeze and -thaw cycles to encourage fracture and disintegration of the
mitochondrial membranes and CS liberation (CSafter), and in a separate snap-
frozen sample of the same muscle on which MAPR was performed after
mechanical homogenisation and complete disintegration of sub-cellular structures
(CStotal).
CSafter and CStotal samples were stored and homogenised in homogenising
buffer (KCl 175 mM and ethylenediaminetetra-acetic acid (EDTA) 2 mM; pH
7.4) and activity was calculated utilising the extinction coefficient for CS of 13.6
[28]. The proportion of CS activity in CSbefore, CSafter and CStotal samples was used
to calculate intact mitochondrial yield for correction of MAPR.
Measurement of Mitochondrial Proteins
Mitochondrial protein content was analysed on snap frozen samples derived from
MS using a Bradford Protein Assay kit in triplicate (Bio-Rad Protein Assay, Bio-
Rad Laboratories, Hercules, CA, USA). Mitochondrial protein was used to correct
for CS activity.
Measurement of Mitochondrial Swelling
Mitochondrial swelling was measured spectrophotometrically in a microplate
assay adapted from [29]. 5 mL of diaphragmatic MS (,10 mg mitochondrial
protein) was added to each well and the assay was initiated via the addition of
90 uL of Solution B containing glutamate, malate and succinate (G+M+S; all
10 mM; [30]). A baseline reading was recorded for 4 mins (excitation
wavelength5490 nm; emission wavelength5525 nm) before the addition of 5 mL
of vehicle control (G+M+S in Solution B) or the appropriate [Ca2+]. An
additional 30 mM [Ca2+] was utilised as a positive control as a known activator of
the mitochondrial permeability transition pore inducing maximal mitochondrial
swelling subsequent to bursting. Mitochondrial swelling was followed for
16 minutes, with a decrease in absorbance indicating increased size of the
mitochondria (n58 for both groups for these experiments).
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Statistics
Results are expressed as mean ¡ standard error of the mean. [Ca2+]-treated
MAPR data is expressed relative to MAPR at 0 nM [Ca2+]. A three-way analysis of
variance (ANOVA) was utilised to detect between group, substrate and muscle
differences in MAPR at 0 nM [Ca2+], and between group, [Ca2+] and muscle
differences in MAPR across the [Ca2+] range. A two-way ANOVA was utilised to
detect between group and muscle differences for CS function, mitochondrial
protein concentration and mitochondrial yield in both TA and diaphragm. A two-
way ANOVA was utilised to detect between group and [Ca2+] difference in
mitochondrial morphology. Subsequent post hoc analysis using Tukey’s test was
utilised to identify interactions between the variables. An a value of 0.05 was
considered significant.
Results
MAPR of mdx mitochondria from diaphragm and TA
This study notably demonstrates that NADH-dependent MAPR is severely
depressed in mdx mitochondria isolated from diaphragm (Figs. 1 and 2; p,0.001)
and TA (Fig. 2; p,0.05) compared to controls and that this depression occurs
irrespective of the oxidizing substrate used to stimulate OXPHOS. Stimulation of
various substrate entry points within the Kreb’s Cycle that mimic the entry points
for glycolytic (P+M), b-fat oxidation (PC+M) and anaplerotic glutamate
oxidation (a-KG) derivatives all produced chronically depressed MAPR in
diaphragmatic mdx mitochondria that was 70% (p,0.005), 67% (p,0.01) and
60% (p,0.01) less than controls, respectively. A similar 75% depression in
diaphragm MAPR was observed when Kreb’s cycle substrates were combined
(PPKM) to stimulate OXPHOS (Fig. 2; p,0.01). This effects was also observed
for TA MAPR, which was 62% less than controls following PPKM stimulation
(p,0.05; Fig. 2). Succinate-induced FADH2-dependent OXPHOS, however,
significantly ameliorated MAPR of mdx diaphragmatic and TA mitochondria
when compared to the NADH-generating PPKM substrate combination
(p,0.05), albeit was still 30% less than control levels (p,0.05). Interestingly, this
effect of the S+R combination on MAPR was not observed in the control group
(p.0.05).
Effects of a ‘‘resting’’ extramitochondrial [Ca2+] spectra on MAPR
Fig. 3 shows the effect of a 50–400 nM extra-mitochondrial [Ca2+]em (normalised
to 0 nM [Ca2+]), on PPKM- and S+R-stimulated MAPR in control and mdx
mitochondria extracted from the diaphragm and TA. Overall, there was no
significant effect of [Ca2+] on MAPR of mdx mitochondria when compared to
controls (p.0.05 group effect). There was a trend towards reduced stimulation of
PPKM-fuelled MAPR in mdx compared to control mitochondria from both
diaphragm (p50.141; Fig. 3A) and TA (p50.069; Fig. 3C) upon addition of
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Fig. 1. MAPR of normal (control C57BL/10) and dystrophicmdx diaphragm at 0 nM extra-mitochondrial
[Ca2+] following pyruvate and malate (P+M), palmitoyl carnitine and malate (PC+M) and a-ketoglutarate
(a-KG) stimulation. ***p,0.005 from controls; **p,0.01 from controls; n510 control and n510 mdx.
doi:10.1371/journal.pone.0115763.g001
Fig. 2. MAPR of normal (control C57BL/10) and dystrophic mdx diaphragm and TA at 0 nM extra-
mitochondrial [Ca2+] following pyruvate + palmitoyl carnitine + a-ketoglutarate + malate (PPKM) and
succinate + rotenone (S+R) stimulation. **p,0.01 from control group; *p,0.05 from control group;
‘p,0.05 from other substrates in mdx group; n510 control & n510 mdx.
doi:10.1371/journal.pone.0115763.g002
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Ca2+em however this observation was not concentration-specific. Irrespective of
group, 400 nM [Ca2+]em inhibited PPKM-stimulated MAPR of diaphragmatic
mitochondria compared to all other [Ca2+]em (all p,0.05); Fig. 3A). A similar
effect was observed for TA mitochondria, with 400 nM Ca2+ inhibiting PPKM-
stimulated MAPR compared to 50 nM and 100 nM (both p,0.05) but not
200 nM [Ca2+]em (p.0.05; Fig. 3C).
For S+R-stimulated MAPR in diaphragm, there again was a trend towards
relative Ca2+-induced MAPR depression (from 0 nM MAPR) in mdx compared to
control mitochondria (p50.074; Fig. 3B). This trend was notably absent in TA
mitochondria (p50.435 mdx versus control; Fig. 3D). There was no effect of
extra-mitochondrial [Ca2+] on S+R-stimulated MAPR at any of the assayed
concentrations for TA mitochondria, irrespective of group (Fig. 3D). In
diaphragm, a 400 nM extramitochondrial [Ca2+] was inhibitory to S+R-induced
MAPR compared to 50 nM and 100 nM [Ca2+]em (both p,0.05) but not to
200 nM (p.0.05; Fig. 3D).
Citrate Synthase activity
All data for CS function is described in Table 1. CSbefore activity (a measure of free
CS availability from damaged mitochondria in the MS) was 40% lower in mdx
Fig. 3. Relative MAPR of normal (control C57BL/10) and dystrophic mdx diaphragm following (A) pyruvate, palmitoyl carnitine, a-ketoglutarate
and malate (PPKM) stimulation; (B) succinate and rotenone (S+R) stimulation; and TA following (C) PPKM stimulation; and (D) S+R stimulation
across a 50–400 nM [Ca2+] range. Data is expressed relative to MAPR at 0 [Ca2+] as mean ¡ SEM. *p,0.05 400 nM different from other [Ca2+]; n510
control & n510 mdx.
doi:10.1371/journal.pone.0115763.g003
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mitochondria from TA and diaphragm compared to controls (p,0.01). CSafter
activity (a measure of the total number of mitochondria that were brought
through the mitochondrial extraction process whether intact or damaged), was
reduced by ,30% in mdx TA and diaphragm (p,0.01) from controls. No
difference was observed between control and mdx groups in the CSbefore:CSafter
ratio, a marker of the robustness of the extracted intact mitochondria that were
available to OXPHOS and therefore MAPR measurement. In a separate
homogenised sample of the same muscle from which mitochondria were isolated,
CStotal activity was unchanged between control and mdx groups in both TA and
diaphragm. A significant decrease in the CSafter:CStotal ratio (p,0.01), which
represents the proportion of possible mitochondria that are able to withstand the
extraction procedure, was observed in mdx muscles, in both diaphragm and TA.
Mitochondrial yield (% of successfully extracted mitochondria in the MS
compared to the total number of mitochondria available for extraction in the
same mass of muscle) was markedly (35%) higher in control compared to mdx
MS (p,0.01).
Comparison of CS function between muscles was also made due to the marked
differences in disease progression between muscles of the lower limb and
diaphragm in mdx mice. Mitochondrial yield was ,20% higher in TA than in
diaphragm (p,0.05) as was the CSafter:CStotal ratio (p,0.01). There was a strong
trend toward increased CStotal activity of the diaphragm compared to TA in both
control and mdx muscle (20%; p50.07), however there were no significant
differences in any of the other CS measures between muscles (CSbefore, CSafter and
CSbefore:CSafter all p.0.05).
Mitochondrial Morphology
Mdx mitochondria were significantly larger (more swollen) as reflect by a reduced
% change from baseline optical density at a 525 nm wavelength in both a Ca2+
free environment and when exposed to increasing [Ca2+]em (p,0.05; Fig. 4).
Irrespective of strain, increasing [Ca2+] induced concomitant increases in
Table 1. Citrate synthase (CS) function and mitochondrial yield (% of total available) and protein content (% of total) of control (c57BL/10) and dystrophic
mdx diaphragm and TA.
CON MDX p values
TA DIA TA DIA Strain Muscle
CSbefore (mmol.mg
21 mitochondrial protein.min21) 1.3¡0.2 1.6¡0.3 0.8¡0.1 0.9¡0.092 0.004** 0.338
CSafter (mmol.mg
21 mitochondrial protein.min21) 11.8¡0.9 11.7¡0.8 8.7¡0.6 8.3¡1.5 0.002** 0.282
CStotal (mmol.mg
21 mitochondrial protein.min21) 55.8¡3.2 67.2¡4.4 53.9¡4.6 64.4¡5.6 0.395 0.071
CSafter:CStotal Ratio 0.20¡0.01 0.15¡0.02 0.17¡0.02 0.13¡0.02 0.009** 0.008**
CSbefore:CSafter Ratio 0.10¡0.02 0.12¡0.02 0.09¡0.01 0.13¡0.02 0.900 0.063
Mitochondrial Yield (%) 18.0¡1.5 13.9¡1.1 15.5¡2.1 10.1¡1.3 0.012* 0.009**
Mitochondrial Protein Content (% of total) 21.6¡2.2 22.1¡0.9 17.5¡0.8 31.3¡2.6 0.499 0.269
*p,0.05 from control group, **p,0.01 from control group; n510 control & n510 mdx for TA and diaphragm.
doi:10.1371/journal.pone.0115763.t001
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mitochondrial size (p,0.05). Notably, there was large variation in the response of
mdx mitochondria to increasing Ca2+em load that was not evident in control
mitochondria.
Discussion
This study confirms compromised ATP production by mdx mitochondria
(MAPR), and in particular, in mitochondria respiring on optimal and continuous
delivery of oxidising substrates. This is an important finding because
mitochondria have been extracted from muscle at a relatively stable period of
disease progression (12 weeks) and thus, the pathophysiology and concomitant
inflammatory nature of the disease is less influential. This suggests an inherent
deficit of the mitochondria, which is likely reflective of strong and persistent
inhibition or structural abnormality of key mitochondrial machinery leading to
deficient OXPHOS. While potentially induced by the extreme pathological
environment in which the mitochondria reside in vivo, a mounting collection of
evidence suggests a natural history of inherited metabolic impairment alongside
dystrophin deficiency. Onopiuk et al. [7] has demonstrated that metabolic
dysfunction is present in dystrophic myoblasts prior to the time of dystrophin
expression [7]. This suggests that while dystrophin-deficiency induced patho-
physiology may exacerbate mitochondrial dysfunction, metabolic impairment
exists beforehand. That female carriers of DMD who do not express the disease
Fig. 4. [Ca2+]-dependent swelling of normal (control C57BL/10) and dystrophic mdx diaphragm
mitochondria respiring on glutamate, malate and succinate (GMS). Data is expressed as the percentage
change from baseline OD at 525 nm. *p,0.05 different from control at all [Ca2+]; **p,0.001 all different from
0 nM [Ca2+] n58 control & n58 mdx.
doi:10.1371/journal.pone.0115763.g004
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exhibit abnormal muscle energy metabolism, especially when ATP demand is
increased during exercise, lends further credence to this notion [31, 32].
Whilst several groups have demonstrated depressed oxygen consumption rate
and isolated mitochondrial enzyme function in dystrophic skeletal muscle [5–
8, 18, 21, 22, 33], we have highlighted the differential contributions of Complex I
and II H+ flux into the ETC and resultant ATP production in dystrophic mouse
mitochondria. Importantly, these impairments were shown in the ‘healthy’
mitochondria that survived the isolation process. MAPR was shown in this study
to be severely depressed by up to 75% of control levels in both diaphragm (Figs. 1
and 2) and TA (Fig. 2) mitochondria from the mdx mouse. MAPR depression was
more evident when stimulated by substrates that enter the TCA cycle (P+M,
PC+M, a-KG and PPKM) and rely on NADH-mediated shuttling of H+ into the
ETC through Complex I. In contrast, the complete inhibition of Complex I with
rotenone and stimulation of Complex II-mediated MAPR with succinate (S+R)
partially ameliorated mdx MAPR, albeit depression was still evident (Fig. 2). This
suggests a problem with NADH flux into the ETC of mdx mitochondria, whereby
NADH is either being sequestered away from, or is unable to be efficiently
oxidised by, Complex I to establish proton motive force. In this instance, the
accumulation of NADH at Complex I would be inhibitory to all dehydrogenases
of the Krebs cycle except for succinate dehydrogenase (including pyruvate,
isocitrate, a-KG dehydrogenase)(as reviewed in [34]), which would explain why
succinate stimulation was able to partially restore MAPR of mdx mitochondria
closer to control levels, whereas other Kreb’s substrates had no effect. Recent
literature has demonstrated reduced Complex I activity in permeabilised skeletal
muscle from mdx mice [33] and in mdx brain, in which dystrophin is normally
expressed but is also notably absent in DMD [35]. The expression of various
Complex I subunits is also evident in mdx skeletal muscle at the protein level
(,1.5 fold decrease), in human DMD skeletal muscle at the transcript level (3–6
fold decrease) [36] and in mdx cardiac muscle. Thus our data together with others
[20, 33] suggests that a persistent impairment of Complex I function underpins
dystrophic pathology, which strongly limits – but does not obliterate – the ATP-
producing capacity of mitochondria. While Godin et al. [33] suggests that reduced
mitochondrial biomass (i.e. Complex expression/activity) underscores loss of ETC
function rather than specific respiratory impairment, our data would suggest the
opposite as the stimulation of respiration with succinate following Complex I
inhibition with rotenone partially restored MAPR in mdx mitochondria with
equivalent biomass.
It has been widely documented that [Ca2+]mit is a positive stimulator of
OXPHOS (reviewed in [37, 38]), but despite dramatic elevations of [Ca2+]mit
within dystrophic skeletal [39] and cardiac [17] muscle, corresponding increases
in OXPHOS do not appear to occur in dystrophic muscle. In our study,
manipulating the [Ca2+]em across a 50–200 nM range (Fig. 3) had no effect on
MAPR in either control or mdx mitochondria. With the exception of relative S+R-
stimulated MAPR in TA, in which control and mdx MAPR were remarkably
comparable, there was a general trend for reduced modulation of MAPR in mdx
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compared to control mitochondria (p values ranging from 0.069 to 0.141),
however this what not statistically significant. Interestingly, in contrast to the lack
of response a 50–200 nM [Ca2+] range effected, the addition of 400 nM [Ca2+em]
induced PPKM-stimulated MAPR depression in both control and mdx
mitochondria from diaphragm and TA (Figs. 3A and 3C), and S+R-stimulated
MAPR depression in both control and mdx mitochondria from diaphragm
(Fig. 3B). While this demonstrates that mdx mitochondria are capable of
responding to [Ca2+]em, and, indeed, that they respond in the same way to this
‘‘upper resting’’ load as per normal control mitochondria, general MAPR
depression at this concentration is an anomalous finding. Several groups have
demonstrated that 400 nM Ca2+ is sufficient to induce activation of key regulatory
enzymes of OXPHOS including PDH and FAD-glycerol-3-phosphate dehydro-
genase (reviewed in [38]), thus a stimulatory effect on MAPR would be expected.
Nevertheless, we have shown the same inhibitory effect induced by 400 nM Ca2+
in control and mdx diaphragm mitochondria for PPKM- and S+R-stimulated
MAPR, suggesting that this effect is not substrate specific and therefore, probably
not a result of enzymatic PDH inhibition.
Remarkably, we were unable to show 400 nM [Ca2+]em-induced MAPR
inhibition in either control or mdx mitochondria from TA, when stimulated with
S+R. This would further suggest that diaphragm and TA respond very differently
to extra-mitochondrial Ca2+ load, and that the target for MAPR inhibition by
400 nM Ca2+ may lie somewhere between Complex I and II, since in TA
mitochondria MAPR inhibition was observed following PPKM- but not S+R-
stimulation. It is interesting to speculate that the inhibitory effect of 400 nM
[Ca2+]em on S+R-stimulated MAPR in mdx diaphragm, but not TA mitochondria
may contribute to the more human DMD-like progressive wasting evident in this
muscle, especially in the instance that Complex I function is impaired in DMD
mitochondria which would increase reliance on FADH2-donated H
+ and electrons
through Complex II. A notable difference between mitochondria from the
predominantly type I fibre-composed diaphragm and type-II fibre-composed TA
is the absence of the mitochondrial calcium binding protein, calmitine. This
protein is expressed only in type I fibres [40], although is notably quantitatively
reduced in mdx mitochondria [41]. It is not known what, if any, role calmitine
plays in directly regulating OXPHOS.
In this study, CS analysis of mdx muscle was performed to determine the
quality of our isolated mitochondria preparations and subsequently normalise
MAPR for comparative mitochondrial damage/loss caused by the extraction
process and available functionality. While CStotal activity was unchanged in
dystrophic mitochondria compared to controls in both TA and diaphragm, thus
indicating comparable CS expression and mitochondrial content, it was
interesting to observe highly significant reductions in the absolute (CSafter) and
functional CS activity (CSbefore) of extracted MS. Taken together with a significant
reduction in the CSafter/CStotal ratio and % mitochondrial yield of mdx muscle
compared to controls, our data suggests that less mdx mitochondria are being
successfully brought through the extraction process. This finding implicates that
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dystrophic mitochondria are more susceptible to damage (mechanical or
biochemical) during the extraction process, than control mitochondria. Increased
fragility of both the inner and outer mitochondrial membranes has been reported
previously in mitochondrial fractions derived from gastrocnemius biopsies of
DMD patients from as early as one year of age [42] – this is an age at which all
muscles show relative stability and normality of function. We have confirmed the
same fragility in mitochondria from 12 week old mdx mice (Table 1) – this is an
age at which the severe cyclical degenerative episodes evident in hind limb muscles
earlier in life have attenuated, and the diaphragm has yet to progress to its severe
wasting phenotype. Mitochondrial membrane fragility following biochemical
isolation is likely associated with the swollen morphology observed in mdx
mitochondria comparative to controls (Fig. 4) which has also been observed by
others [43], and, was apparent both prior to and following the addition of
increasing [Ca2+] to the extramitochondrial environment. [Ca2+] load, however,
did not induce any faster swelling of mdx mitochondria. This finding is in
accordance with Reutenauer et al. [44] who demonstrated comparable responses
to Ca2+ challenge between biochemically isolated control and mdx mitochondria,
with the calcium retention capacity and Ca2+ overload concentration required to
induce permeability transition following repeat 5 mM Ca2+ bursts, equivalent [39].
In contrast, Godin et al. [33] has shown a greater susceptibility (decreased time)
to permeability transition pore opening and a reduced Ca2+_ retention capacity in
isolated fibres from the mdx mouse, highlighting differences in the behaviour
between in vivo and in vitro mitochondrial morphology. Indeed, it is interesting
that swelling was persistent despite mitochondria bathing in a low Ca2+em
environment throughout the isolation procedure, storage and the Ca2+-free
swelling assay in our study, which suggests that mdx mitochondria have a swollen
morphological phenotype that is less responsive or unable to respond to
subsequent reductions in the concentration of the Ca2+em environment.
Alternatively, this finding may reflect an artefact of our biochemical isolation
technique as subsarcolemmal mitochondrial size is demonstrably comparable
between mdx and control muscles in vivo, as detected by transmission electron
microscopy [20]. As the subsarcolemmal mitochondrial pool accounts for only
,10% of total skeletal muscle mitochondria and the comparative morphology of
mdx intrafibrillar mitochondria (which account for ,90% of total mitochondria)
is yet to be assessed [20], further characterisation of mitochondrial swelling is
clearly required.
In summary, we have demonstrated reduced MAPR in mitochondria extracted
from diaphragm and TA from the mdx mouse model of DMD. As this reduction
can be partially ameliorated by bypassing Complex I and directly stimulating
Complex II, it suggests that Kreb’s-fuelled NADH-dependent Complex I function
is deficient. We have also demonstrated a tendency for MAPR to be modulated
differently by the addition of Ca2+ to the extra-mitochondrial environment in
mdx compared to control mitochondria, though in a non-concentration-
dependent manner. Further, we have shown depression of PPKM-stimulated
MAPR in the presence of 400 nM [Ca2+]em in both diaphragm and TA, and S+R-
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stimulated MAPR in diaphragm in both control and mdx mitochondria. We
cannot conclude if these findings are reflective of a pre-existing state either
inherent to the DMD phenotype or induced by an in vivo pathophysiological
environment that produces persistent morphological maladaptation. As such,
further investigation is required to characterise the precise bioenergetical profile
of mdx mitochondria and the fragility of mitochondrial membranes. Extension of
our findings to determine whether Complex I deficiency worsens with age and/or
repeat exposure to cyclical damage bouts, is present in other forms of muscular
dystrophy characterised by intracellular Ca2+ dysregulation, and/or underscores
the cardiac muscle pathology evident in DMD, would be of value to the current
body of literature.
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